Overall, given the percentage of ROS1-positive NSCLC patients, and supported by the positive clinical results obtained for several ROS1 inhibitors, ROS1 testing should be routinely used during the anamnestic process of NSCLC, both naïve and treatment-resistant. Here, ROS1 is linked to non-small cell lung carcinoma.